Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done

An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...

CRSP Stock: The First CRISPR Gene-Editing Drug Could Be Here Sooner Than You Think

Crispr Therapeutics (CRSP) said Tuesday it will begin asking the Food and Drug Administration to approve what would be the first-ever gene-editing treatment to hit the market using the CRISPR technolo...

Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success

Text size Intellia CEO John Leonard called the results a vindication of the company’s modular approach to Crispr therapies. Courtesy Intellia Therapeutics Patients who got a one-time gene-editin...

Roku, Tesla, and Other Cathie Wood Favorites Are Falling

Text size Ark Invest CEO Cathie Wood. Courtesy of ARK Cathie Wood’s $12 billion flagship exchange-traded fund was falling again in Monday trading. It is another sign that “innovation stocks” such as R...

Stocks Are on a Wild Ride. 20 Bargains to Buy Now, According to Barron’s Roundtable Experts.

Fed be nimble, Fed be quick. The quicker, the better, in fact. Hike interest rates, shrink your balance sheet, and let’s be done with it all before the stock market sinks even further. The market’s re...